Drug intelligence / Profile preview

REP 2139-Mg + peginterferon alfa-2a + tenofovir disoproxil fumarate

Development stage: Unknown
Lead developer: Replicor
Modality: Small Molecules, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intravenous, Subcutaneous, Oral

Overview

This drug is a combination therapy consisting of REP 2139-Mg (a magnesium chelate nucleic acid polymer), peginterferon alfa-2a (a pegylated form of recombinant human interferon alfa-2a), and tenofovir disoproxil fumarate (a nucleotide reverse transcriptase inhibitor). REP 2139-Mg is designed to clear hepatitis B virus surface antigen (HBsAg), which enables restoration of immune control over HBV and HDV infections. Peginterferon alfa-2a acts as an immunomodulatory cytokine that upregulates interferon-stimulated genes and bolsters antiviral immune responses. Tenofovir disoproxil fumarate inhibits viral reverse transcriptase, limiting replication of hepatitis B virus. This triple combination is primarily being investigated for the treatment of chronic hepatitis B and hepatitis D (HDV) infections, particularly in patients with cirrhosis and those unresponsive to other therapies[8][4][1].

Other names: peginterferon alpha-2atenofovirTDF

Targets

HBV Pol (Hepatitis B virus polymerase)IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on REP 2139-Mg + peginterferon alfa-2a + tenofovir disoproxil fumarate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REP 2139-Mg + peginterferon alfa-2a + tenofovir disoproxil fumarate.

Explore the full profile